|
1
|
du Bois A, Lück HJ, Meier W, et al: A
randomized clinical trial of cisplatin/paclitaxel versus
carboplatin/paclitaxel as first-line treatment of ovarian cancer. J
Natl Cancer Inst. 95:1320–1329. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kitawaki J, Ishihara H, Koshiba H, et al:
Usefulness and limits of CA-125 in diagnosis of endometriosis
without associated ovarian endomeriomas. Hum Reprod. 20:1999–2003.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ozols RF, Bundy BN, Greer BE, et al: Phase
III trial of carboplatin and paclitaxel compared with cisplatin and
paclitaxel in patients with optimally resected stage III ovarian
cancer: A Gynecologic Oncology Group study. J Clin Oncol.
21:3194–3200. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Uekuri C, Shigetomi H, Ono S, Sasaki Y,
Matsuura M and Kobayashi H: Toward an understanding of the
pathophysiology of clear cell carcinoma of the ovary (Review).
Oncol Lett. 6:1163–1173. 2013.PubMed/NCBI
|
|
5
|
Old WM, Meyer-Arendt K, Aveline-Wolf L, et
al: Comparison of label-free methods for quantifying human proteins
by shotgun proteomics. Molecular & cellular proteomics. Mol
Cell Proteomics. 4:1487–1502. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Toyama A, Suzuki A, Shimada T, et al:
Proteomic characterization of ovarian cancers identifying
annexin-A4, phosphoserine amino-transferase, cellular retinoic
acid-binding protein 2, and serpin B5 as histology-specific
biomarkers. Cancer Sci. 103:747–755. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamamoto T, Kudo M, Peng WX and Naito Z:
Analysis of protein expression regulated by lumican in PANC-1 cells
using shotgun proteomics. Oncol Rep. 30:1609–1621. 2013.PubMed/NCBI
|
|
8
|
Wang JJ, Liu Y, Zheng Y, Lin F, Cai GF and
Yao XQ: Comparative proteomics analysis of colorectal cancer. Asian
Pac J Cancer Prev. 13:1663–1666. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu Y, Wu R, Sangha N, et al:
Classifications of ovarian cancer tissues by proteomic patterns.
Proteomics. 6:5846–5856. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Morgan TM, Seeley EH, Fadare O, Caprioli
RM and Clark PE: Imaging the clear cell renal cell carcinoma
proteome. J Urol. 189:1097–1103. 2013. View Article : Google Scholar :
|
|
11
|
Tan Y, Ma SY, Wang FQ, et al:
Proteomic-based analysis for identification of potential serum
biomarkers in gallbladder cancer. Oncol Rep. 26:853–859.
2011.PubMed/NCBI
|
|
12
|
Jiang X, Jiang X, Feng S, Tian R, Ye M and
Zou H: Development of efficient protein extraction methods for
shotgun proteome analysis of formalin-fixed tissues. J Proteome
Res. 6:1038–1047. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sprung RW Jr, Brock JW, Tanksley JP, et
al: Equivalence of protein inventories obtained from formalin-fixed
paraffin-embedded and frozen tissue in multidimensional liquid
chromatography-tandem mass spectrometry shotgun proteomic analysis.
Mol Cell Proteomics. 8:1988–1998. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kawamura T, Nomura M, Tojo H, et al:
Proteomic analysis of laser-microdissected paraffin-embedded
tissues: (1) stage-related protein candidates upon non-metastatic
lung adenocarcinoma. J Proteomics. 73:1089–1099. 2010. View Article : Google Scholar
|
|
15
|
Bateman NW, Sun M, Bhargava R, et al:
Diffetential proteomic analysis of late-stage and recurrent breast
cancer from formalin-fixed paraffin-embedded tissues. J Proteome
Res. 10:1323–1332. 2011. View Article : Google Scholar
|
|
16
|
Naidoo K, Jones R, Dmitrovic B, et al:
Proteome of formalin-fixed paraffin-embedded pancreatic ductal
adenocarcinoma and lymph node metastases. J Pathol. 226:756–763.
2012. View Article : Google Scholar
|
|
17
|
Rodriguez-Rigueiro T, Valladares-Ayerbes
M, Haz-Conde M, et al: A novel procedure for protein extraction
from formalin-fixed paraffin-embedded tissues. Proteomics.
11:2555–2559. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamada K, Tachibana T, Hashimoto H, et al:
Establishment and characterization of cell lines derived from
serous adenocarcinoma (JHOS-2) and clear cell adenocarcinoma
(JHOC-5, JHOC-6) of human ovary. Hum Cell. 12:131–138. 1999.
|
|
19
|
Hayashi M, Okuda T, Chiba H, Nagatsuka M
and Okai T: The analysis of toll-like receptor signal pathway in
human ovarian cancer cells. J Showa Med Assoc. 70:211–221.
2010.
|
|
20
|
Yamamoto T, Matsuda Y, Kawahara K, Naito Z
and Ishiwata T: Keratinocyte growth factor stimulates growth of MIA
PaCa-2 cells through extracellular signal-regulated kinase
phosphorylation. Oncol Lett. 3:307–310. 2012.PubMed/NCBI
|
|
21
|
Bluemlein K and Ralser M: Monitoring
protein expression in whole-cell extracts by targeted label- and
standard-free LC-MS/MS. Nat Protoc. 6:859–869. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zybailov B, Coleman MK, Florens L and
Washburn MP: Correlation of relative abundance ratios derived from
peptide ion chromatograms and spectrum counting for quantitative
proteomic analysis using stable isotope labeling. Anal Chem.
77:6218–6224. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
de Hoon MJ, Imoto S, Nolan J and Miyano S:
Open source clustering software. Bioinformatics. 20:1453–1454.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Saldanha AJ: Java Treeview - extensible
visualization of microarray data. Bioinformatics. 20:3246–3248.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cotoi CG, Khorsandi SE, Pleşea IE and
Quaglia A: Whole- genome DASL gene expression profiling of
hepatocellular carcinoma sub-populations isolated by laser
microdissection on formalin-fixed and paraffin-embedded liver
tissue samples. Rom J Morphol Embryol. 53:893–902. 2012.
|
|
26
|
Kotorashvili A, Ramnauth A, Liu C, et al:
Effective DNA/RNA co-extraction for analysis of microRNAs, mRNAs,
and genomic DNA from formalin-fixed paraffin-embedded specimens.
PLoS One. 7:e346832012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakanishi Y, Shimizu T, Tsujino I, et al:
Semi-nested real-time reverse transcription polymerase chain
reaction methods for the successful quantitation of cytokeratin
mRNA expression levels for the subtyping of non-small-cell lung
carcinoma using paraffin-embedded and microdissected lung biopsy
specimens. Acta Histochem Cytochem. 46:85–96. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Feldman AS, Banyard J, Wu CL, McDougal WS
and Zetter BR: Cystatin B as a tissue and urinary biomarker of
bladder cancer recurrence and disease progression. Clin Cancer Res.
15:1024–1031. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee M-J, Yu G-R, Park S-H, et al:
Identification of cystatin B as a potential serum marker in
hepatocellular carcinoma. Clin Cancer Res. 14:1080–1089. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rivenbark AG and Coleman WB: Epigenetic
regulation of cystatins in cancer. Front Biosci (Landmark Ed).
14:453–462. 2009. View
Article : Google Scholar
|
|
31
|
Keppler D: Towards novel anti-cancer
strategies based on cystatin function. Cancer Lett. 235:159–176.
2006. View Article : Google Scholar
|
|
32
|
Kos J and Lah TT: Cysteine proteinases and
their endogenous inhibitors: Target proteins for prognosis,
diagnosis and therapy in cancer (Review). Oncol Rep. 5:1349–1361.
1998.PubMed/NCBI
|
|
33
|
Gashenko EA, Lebedeva VA, Brak IV,
Tsykalenko EA, Vinokurova GV and Korolenko TA: Evaluation of serum
procathepsin B, cystatin B and cystatin C as possible biomarkers of
ovarian cancer. Int J Circumpolar Health. 72:212152013. View Article : Google Scholar
|
|
34
|
Masuishi Y, Arakawa N, Kawasaki H, Miyagi
E, Hirahata F and Hirano H: Wild-type p53 enhances annexin IV gene
expression in ovarian clear cell adenocarcinoma. FEBS J.
278:1470–1483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim A, Enomoto T, Serada S, et al:
Enhanced expression of Annexin A4 in clear cell carcinoma of the
ovary and its association with chemoresistance to carboplatin. Int
J Cancer. 125:2316–2322. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mogami T, Yokota N, Asai-Sato M, et al:
Annexin A4 is involved in proliferation, chemo-resistance and
migration and invasion in ovarian clear cell adenocarcinoma cells.
PLos One. 8:e803592013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kajihara H, Yamada Y, Kanayama S, et al:
Clear cell carcinoma of the ovary: Potential pathogenic mechanisms
(Review). Oncol Rep. 23:1193–1203. 2010.PubMed/NCBI
|
|
38
|
Tsuchiya A, Sakamoto M, Yasuda J, et al:
Expression profiling in ovarian clear cell carcinoma:
identification of hepatocyte nuclear factor-1 beta as a molecular
marker and a possible molecular target for therapy of ovarian clear
cell carcinoma. Am J Pathol. 163:2503–2512. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Duncan R, Carpenter B, Main LC, Telfer C
and Murray GI: Characterisation and protein expression profiling of
annexins in colorectal cancer. Br J Cancer. 98:426–433. 2008.
View Article : Google Scholar
|
|
40
|
Lin L-L, Huang H-C and Juan H-F: Revealing
the molecular mechanism of gastric cancer marker annexin A4 in
cancer cell proliferation using exon arrays. PLoS One.
7:e446152012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zimmermann U, Balabanov S, Giebel J, et
al: Increased expression and altered location of annexin IV in
renal clear cell carcinoma: a possible role in tumour
dissemination. Cancer Lett. 209:111–118. 2004. View Article : Google Scholar : PubMed/NCBI
|
